Canadian cohort expanded-access program of nivolumab plus ipilimumab in advanced melanoma.
Conclusions: In this Canadian population, nivolumab plus ipilimumab demonstrated a safety profile and survival outcomes consistent with phase ii and iii clinical trial data.
PMID: 32905202 [PubMed - as supplied by publisher]
Source: Current Oncology - Category: Cancer & Oncology Tags: Curr Oncol Source Type: research
More News: Canada Health | Cancer & Oncology | Clinical Trials | Melanoma | Skin Cancer | Toxicology | USA Health | Yervoy